Partnering in Life Sciences

As an experienced partnering expert in life sciences EBD Group operates at the point where biotechnology and pharmaceutical companies converge. In these markets it is partnerships, and not simply products, that are driving growth.

As a conference partner, EBD Group offers services that can add value to existing events in the form of advanced partnering meeting management, supported by its powerful partneringONE software.

As a consulting partner, EBD Group offers comprehensive consulting and advisory services in a number of areas that center around licensing, corporate strategy, due diligence, marketing and management.



MARKET TRENDS

Over $20 billion in partnering transactions have been concluded each year for the past four years in bio-tech with sometimes dramatic results for both major pharmaceutical companies and smaller biotechs. EBD Group believes the coming years will see deal-making rise significantly from the curent plateau to achieve extraordinary new levels.

The Next-Big-Thing . . . Is Not A Drug, predicts BioWorld, the daily journal tracking trends in the biotechnology and pharmaceutical markets. While drugs continue to dominate conversation, a transaction trend is driving a converging industry that is "abuzz with news of deals," says BioWorld.

"Online collaboration is the future," said Carola Schropp, Managing Partner for the EBD Group. "The next stage of service at EBD is to create anytime, anywhere partnering across the globe to accelerate relationships."